Search

Your search keyword '"Goff, A."' showing total 278 results
Start Over Author "Goff, A." Journal schizophrenia research
278 results on '"Goff, A."'

2. Longitudinal study of inflammation and relapse in schizophrenia

Author

Miller, Brian J., Lemos, Henrique, Schooler, Nina R., Goff, Donald C., Kopelowicz, Alexander, Lauriello, John, Manschreck, Theo, Mendelowitz, Alan, Miller, Del D., Severe, Joanne B., Wilson, Daniel R., Ames, Donna, Bustillo, Juan, Kane, John M., Rapaport, Mark H., and Buckley, Peter F.

Published
2023
Full Text
View/download PDF

10. The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project

Author

Blokland, Gabriëlla A.M., del Re, Elisabetta C., Mesholam-Gately, Raquelle I., Jovicich, Jorge, Trampush, Joey W., Keshavan, Matcheri S., DeLisi, Lynn E., Walters, James T.R., Turner, Jessica A., Malhotra, Anil K., Lencz, Todd, Shenton, Martha E., Voineskos, Aristotle N., Rujescu, Dan, Giegling, Ina, Kahn, René S., Roffman, Joshua L., Holt, Daphne J., Ehrlich, Stefan, Kikinis, Zora, Dazzan, Paola, Murray, Robin M., Di Forti, Marta, Lee, Jimmy, Sim, Kang, Lam, Max, Wolthusen, Rick P.F., de Zwarte, Sonja M.C., Walton, Esther, Cosgrove, Donna, Kelly, Sinead, Maleki, Nasim, Osiecki, Lisa, Picchioni, Marco M., Bramon, Elvira, Russo, Manuela, David, Anthony S., Mondelli, Valeria, Reinders, Antje A.T.S., Falcone, M. Aurora, Hartmann, Annette M., Konte, Bettina, Morris, Derek W., Gill, Michael, Corvin, Aiden P., Cahn, Wiepke, Ho, New Fei, Liu, Jian Jun, Keefe, Richard S.E., Gollub, Randy L., Manoach, Dara S., Calhoun, Vince D., Schulz, S. Charles, Sponheim, Scott R., Goff, Donald C., Buka, Stephen L., Cherkerzian, Sara, Thermenos, Heidi W., Kubicki, Marek, Nestor, Paul G., Dickie, Erin W., Vassos, Evangelos, Ciufolini, Simone, Reis Marques, Tiago, Crossley, Nicolas A., Purcell, Shaun M., Smoller, Jordan W., van Haren, Neeltje E.M., Toulopoulou, Timothea, Donohoe, Gary, Goldstein, Jill M., Seidman, Larry J., McCarley, Robert W., and Petryshen, Tracey L.

Published
2018
Full Text
View/download PDF

12. Longitudinal study of inflammation and relapse in schizophrenia

Author

Brian J. Miller, Henrique Lemos, Nina R. Schooler, Donald C. Goff, Alexander Kopelowicz, John Lauriello, Theo Manschreck, Alan Mendelowitz, Del D. Miller, Joanne B. Severe, Daniel R. Wilson, Donna Ames, Juan Bustillo, John M. Kane, Mark H. Rapaport, and Peter F. Buckley

Subjects
Psychiatry and Mental health, Biological Psychiatry
Published
2023

14. A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy

Author

Jarskog, L. Fredrik, Lowy, Martin T., Grove, Richard A., Keefe, Richard S.E., Horrigan, Joseph P., Ball, M. Patricia, Breier, Alan, Buchanan, Robert W., Carter, Cameron S., Csernansky, John G., Goff, Donald C., Green, Michael F., Kantrowitz, Joshua T., Keshavan, Matcheri S., Laurelle, Marc, Lieberman, Jeffrey A., Marder, Stephen R., Maruff, Paul, McMahon, Robert P., Seidman, Larry J., and Peykamian, Margaret A.

Published
2015
Full Text
View/download PDF

19. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia

Author

Javitt, Daniel C., Buchanan, Robert W., Keefe, Richard S.E., Kern, Robert, McMahon, Robert P., Green, Michael F., Lieberman, Jeffrey, Goff, Donald C., Csernansky, John G., McEvoy, Joseph P., Jarskog, Fred, Seidman, Larry J., Gold, James M., Kimhy, David, Nolan, Karen S., Barch, Deanna S., Ball, M. Patricia, Robinson, James, and Marder, Stephen R.

Published
2012
Full Text
View/download PDF

20. Air pollution and hippocampal atrophy in first episode schizophrenia

Author

Donald C. Goff, Jijun Wang, Botao Zeng, Daphne J. Holt, Oliver Freudenreich, Michelle A. Worthington, Iruma Bello, Renrong Wu, Yingying Tang, Eva Petkova, Babak A. Ardekani, Xiaoduo Fan, Erica D. Diminich, Jingping Zhao, and Corrine Cather

Subjects
China, medicine.medical_treatment, Physiology, Hippocampal formation, Citalopram, medicine.disease_cause, Hippocampus, 03 medical and health sciences, 0302 clinical medicine, Atrophy, Air Pollution, medicine, Humans, Cities, Antipsychotic, Biological Psychiatry, First episode, business.industry, medicine.disease, 030227 psychiatry, Psychiatry and Mental health, Schizophrenia, Biomarker (medicine), business, 030217 neurology & neurosurgery, Oxidative stress, medicine.drug
Abstract

Air pollution has recently been linked to central nervous system (CNS) diseases, possibly mediated by inflammation and oxidative stress. Hippocampal atrophy in individuals with first episode schizophrenia (FES) has also been associated with biomarkers of inflammation and oxidative stress, whereas hippocampal atrophy was not observed in matched healthy controls with similar biomarker levels of inflammation and oxidative stress. Fine particulate matter (PM2.5), one component of air pollution, is most strongly implicated in CNS disease. The present study examined the association between PM2.5 and hippocampal volume in individuals with FES who participated in a 52-week placebo-controlled clinical trial of citalopram added to clinician-determined antipsychotic treatment at four sites in the US and China. Left hippocampal volumetric integrity (LHVI; inversely related to atrophy) was measured at baseline and week 52 using an automated highly-reliable algorithm. Mean annual PM2.5 concentrations were obtained from records compiled by the World Health Organization. The relationships between baseline LHVI and PM2.5 and change in LHVI and PM2.5 were evaluated using regression analyses. 89 participants completed imaging at baseline and 46 participants completed imaging at week 52. Mean annual PM2.5 was significantly associated with both baseline LHVI and change in LHVI after controlling for age, sex, baseline LHVI, duration of untreated psychosis and baseline antipsychotic medication dose. Air pollution may contribute to the progression of hippocampal atrophy after a first episode of illness, but these findings should be considered preliminary since other unmeasured factors may have differed between cities and contributed to the observed effect.

Published
2020

33. Exposure to Epstein Barr virus and cognitive functioning in individuals with schizophrenia

Author

Glen Ford, Cassie Stallings, Christina L.G. Savage, Kelly C. Rowe, Amalia Squire, Sunil Khushalani, Andrea Origoni, Tanya T. Nguyen, Faith Dickerson, Donald C. Goff, Emily Katsafanas, Alan Breier, Robert H. Yolken, Lorraine Jones-Brando, Theresa Newman, and Kevin Sweeney

Subjects
Epstein-Barr Virus Infections, Herpesvirus 4, Human, viruses, medicine.disease_cause, Antibodies, Viral, Article, 03 medical and health sciences, 0302 clinical medicine, Cognition, Social cognition, hemic and lymphatic diseases, medicine, Humans, Effects of sleep deprivation on cognitive performance, Cognitive skill, Antigens, Viral, Biological Psychiatry, biology, business.industry, medicine.disease, Epstein–Barr virus, 030227 psychiatry, Psychiatry and Mental health, Schizophrenia, Immunology, biology.protein, Etiology, Antibody, business, 030217 neurology & neurosurgery
Abstract

Cognitive deficits are a central feature of schizophrenia whose etiology is not fully understood. Epstein Barr Virus (EBV) is a potentially neurotropic infectious agent that can generate persistent infections with immunomodulatory effects. Previous studies have found an association between EBV antibodies and cognitive functioning in different populations, but there has been limited investigation in schizophrenia. In this study, 84 individuals with schizophrenia were administered a comprehensive neuropsychological battery, the MATRICS Consensus Cognitive Battery (MCCB). Participants also provided a blood sample, from which antibodies to the EBV whole virion and specific proteins were measured. Multivariate models were constructed to determine the association between these antibodies and cognitive performance on the MCCB overall and domain scores. Using these models, we found a significant association between the MCCB overall percent composite score and level of antibodies to the EBV Nuclear Antigen-1 (EBNA-1) protein, the Viral Capsid Antigen (VCA) protein, and the EBV whole virion. A significant association was also found for the MCCB social cognition domain with the level of antibodies to the EBV Nuclear Antigen-1 (EBNA-1) protein, the Viral Capsid Antigen (VCA) protein, and the EBV whole virion. In all cases, a higher level of antibodies was associated with a lower level cognitive performance. These findings suggest that exposure to EBV may contribute to cognitive deficits in schizophrenia, a finding which may have implications for new methods of prevention and treatment.

Published
2020

34. D-cycloserine augmentation of cognitive behavioral therapy for delusions: A randomized clinical trial

Author

Donald C. Goff, Andrea B. Troxel, David Kingdon, Faith Dickerson, Kamber L. Hart, Pamela Rakhshan Rouhakhtar, Corinne Cather, Erica D. Diminich, Iruma Bello, and Chenxiang Li

Subjects
Adult, medicine.medical_specialty, Antimetabolites, medicine.medical_treatment, Placebo, Delusions, law.invention, 03 medical and health sciences, 0302 clinical medicine, Delusion, Randomized controlled trial, Double-Blind Method, law, medicine, Humans, Biological Psychiatry, Response rate (survey), Cognitive Behavioral Therapy, business.industry, Therapeutic effect, Cognitive flexibility, Combined Modality Therapy, 030227 psychiatry, Cognitive behavioral therapy, Psychiatry and Mental health, Distress, Treatment Outcome, Cycloserine, Physical therapy, medicine.symptom, business, 030217 neurology & neurosurgery
Abstract

Objective: D-cycloserine (DCS) promotes consolidation of extinction learning. This study extends earlier work by examining whether DCS can enhance cognitive behavioral therapy (CBT) for delusions. Methods: adults reporting moderate or greater delusions were randomly assigned to receive 50 mg of DCS or placebo prior to 10 weekly CBT sessions. The primary outcome was change in severity of delusions measured with the Psychotic Symptom Rating Scale delusion subscale (PSYRATS-D). Secondary outcomes included persistence of response at 3 and 6 month follow-up and the effects of DCS on memory consolidation and cognitive flexibility. Fifty-eight participants were randomized and 44 completed the trial. Results: the DCS and placebo groups did not differ in change from baseline to end of CBT on PSYRATS-D, nor did DCS improve memory consolidation or cognitive flexibility compared to placebo. However, at the 3 month follow-up visit (week 24), 47% of participants who completed treatment with DCS reported a 20% or greater decrease on PSYRATS-D compared to 15% in the placebo group (p =.04). Change in distress across CBT sessions interacted with treatment group to predict change from baseline to week 24 in PSYRATS-D total score (p =.03) such that response at week 24 was greatest in DCS-treated participants who experienced a decrease in distress during CBT sessions. Conclusions: DCS augmentation of CBT did not improve delusions compared to placebo during treatment; however, DCS was associated with a higher response rate at 3-month follow-up. DCS may produce a delayed therapeutic effect, associated with successful CBT sessions, but this finding requires replication.

Published
2020

36. Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?

Author

Alan Mendelowitz, Theo C. Manschreck, Anilkumar Pillai, Juan R. Bustillo, Peter F. Buckley, Joanne B. Severe, John M. Kane, Nina R. Schooler, John Lauriello, Alex Kopelowicz, Del D. Miller, Stephen W. Looney, Donna Ames, Diya Peter, Daniel R. Wilson, and Donald C. Goff

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Exacerbation, medicine.medical_treatment, 03 medical and health sciences, Drug Delivery Systems, 0302 clinical medicine, Predictive Value of Tests, Recurrence, Internal medicine, medicine, Humans, Prospective Studies, Antipsychotic, Psychiatry, Biological Psychiatry, Psychiatric Status Rating Scales, Brain-derived neurotrophic factor, Risperidone, Receiver operating characteristic, Brain-Derived Neurotrophic Factor, Middle Aged, medicine.disease, United States, 030227 psychiatry, Clinical trial, Psychiatry and Mental health, Psychotic Disorders, ROC Curve, Schizophrenia, Biomarker (medicine), Female, Psychology, 030217 neurology & neurosurgery, Antipsychotic Agents, medicine.drug
Abstract

Understanding the biological processes that underlie why patients relapse is an issue of fundamental importance to the detection and prevention of relapse in schizophrenia. Brain Derived Neurotrophic Factor (BDNF), a facilitator of brain plasticity, is reduced in patients with schizophrenia. In the present study, we examined whether decreases in plasma BDNF levels could be used as a biological predictor of relapse in schizophrenia. A total of 221 patients were prospectively evaluated for relapse over 30months in the Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared to Injectables: eValuating Efficacy (PROACTIVE) study. Serial blood samples were collected at a maximum of 23 time points during the 30-month trial and BDNF levels were measured in plasma samples by ELISA. Receiver Operating Characteristic (ROC) curve analysis indicated that BDNF was not a significant predictor of relapse, hospitalization or exacerbation. Regardless of treatment group (oral second generation antipsychotic vs. long-acting injectable risperidone microspheres), baseline BDNF value did not differ significantly between those who experienced any of the adverse outcomes and those who did not. While contrary to the study hypothesis, these robust results offer little support for the use of plasma BDNF alone as a biomarker to predict relapse in schizophrenia.

Published
2018

50. Optical coherence tomography of the retina in schizophrenia: Inter-device agreement and relations with perceptual function

Author

Laura J. Balcer, Margaret K Miller, Pamela D. Butler, Rachel Nolan-Kenney, Donald C. Goff, Michelle A. Worthington, Lisena Hasanaj, and Vance Zemon

Subjects
Retinal Ganglion Cells, medicine.medical_specialty, Visual acuity, genetic structures, Nerve fiber layer, Pilot Projects, Retina, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Nerve Fibers, Optical coherence tomography, Ophthalmology, medicine, Humans, Biological Psychiatry, medicine.diagnostic_test, business.industry, Retinal, eye diseases, 030227 psychiatry, Psychiatry and Mental health, medicine.anatomical_structure, chemistry, Visual function, Schizophrenia, Cirrus, sense organs, medicine.symptom, business, 030217 neurology & neurosurgery, Tomography, Optical Coherence, Schizophrenia spectrum
Abstract

Background Optical coherence tomography (OCT) studies have demonstrated differences between people with schizophrenia and controls. Many questions remain including the agreement between scanners. The current study seeks to determine inter-device agreement of OCT data in schizophrenia compared to controls and to explore the relations between OCT and visual function measures. Methods Participants in this pilot study were 12 individuals with schizophrenia spectrum disorders and 12 age- and sex-matched controls. Spectralis and Cirrus OCT machines were used to obtain retinal nerve fiber layer (RNFL) thickness and macular volume. Cirrus was used to obtain ganglion cell layer + inner plexiform layer (GCL + IPL) thickness. Visual function was assessed with low-contrast visual acuity and the King-Devick test of rapid number naming. Results There was excellent relative agreement in OCT measurements between the two machines, but poor absolute agreement, for both patients and controls. On both machines, people with schizophrenia showed decreased macular volume but no difference in RNFL thickness compared to controls. No between-group difference in GCL + IPL thickness was found on Cirrus. Controls showed significant associations between King-Devick performance and RNFL thickness and macular volume, and between low-contrast visual acuity and GCL + IPL thickness. Patients did not show significant associations between OCT measurements and visual function. Conclusions Good relative agreement suggests that the offset between machines remains constant and should not affect comparisons between groups. Decreased macular volume in individuals with schizophrenia on both machines supports findings of prior studies and provides further evidence that similar results may be found irrespective of OCT device.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results